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The myeloproliferative neoplasm of essential 
thrombocythemia is characterized by a sustained 
peripheral blood thrombocytosis, increased numbers 
of morphologically abnormal megakaryocytes in the 
bone marrow and clinically by episodes of thrombosis 
or hemorrhage and the propensity to transform into 
myelofibrosis or acute myeloid leukemia. The main 
treatment goals are therefore to prevent thrombotic 
events and to inhibit transformation with antiplate-
let and myelosuppressive drugs, respectively. The 
pathogenesis of essential thrombocythemia is largely 
defined by three types of driver mutation, namely the 
JAK2 V617F, CALR exon 9 and MPL exon 10 muta-
tions. Significant improvements have been in the 
treatment of the related myeloproliferative neoplasm 
of primary myelofibrosis with JAK1/2 inhibitors, but 
agents such as interferon and anagrelide remain 
relevant therapeutic options in the modern treatment 
algorithm for essential thrombocythemia [1]. While 
hydroxyurea appears to have no effect in inducing 
molecular responses, reductions in the CALR mutation 
allele burden have been described in some essential 
thrombocythemia patients treated with interferon 
alpha and the JAK1/2 inhibitor ruxolitinib [2, 3]. Any 
effect of anagrelide on the mutant CALR allele burden 
in any essential thrombocythemia patients has not 
been previously described. 
A 75-year old male presented with an isolated 
thrombocytosis of 703 • 109/l. Bone marrow morpho-
logy was consistent with a diagnosis of essential 
thrombocythemia with clustering of increased, 
hyperlobulated megakaryocytes and focal reticulin 
deposition. The JAK2 V617F was not detected. The 
patient commenced aspirin (75 mg) immediately 
and was monitored. Due to an increasing platelet 
count (801 • 109/l) and white cell count (20.2 • 109/l), 
hydroxyurea (500 mg) was started 25 months post 
diagnosis. In the absence of a hematological response 
(platelet count 642 • 109/l), anagrelide (0.5 mg once 
daily) was added increasing to 1.0 mg and 1.5 mg once 
daily over the following eight months with the pa-
tient achieving a hematological remission (platelet 
count 251 • 109/l and white cell count 4.2 • 109/l). 
At 55 months post-diagnosis, CALR mutation analysis 
was performed on peripheral blood genomic DNA 
as previously described [4] and detected a 52 base 
pair deletion (type 1 mutation) in CALR exon 9 with 
an allele burden of 54.2%. Retrospective evaluation 
of the archival peripheral blood DNA from diagnosis 
revealed the same mutation present at an allele burden 
of 36.7%. The platelet count (321 • 109/l) and white 
cell count (7.0 • 109/l) remain within normal range.
Despite anagrelide therapy, no impact on the CALR 
mutation allele burden was evident in this instance. 
While some emerging evidence suggests that driver 
mutation status may impact on the clinical response 
[5, 6], the above observation is broadly in line with the 
finding that in essential thrombocythemia, anagrelide 
therapy also does not impact on the JAK2 V617F allele 
burden [7, 8]. While interferon and JAK1/2 inhibitors 
are known to exert some of their effects through 
disruption of immune responses, the full mechanism 
of action of anagrelide remains unclear with the prima-
ry effect being inhibition of megakaryocyte maturation 
and proplatelet formation [9]. This inability to directly 
target the malignant clone may reflect the inability 
of anagrelide to induce molecular responses in es-
sential thrombocythemia, if indeed deep responses 
are required for long-term survival. This observation 
requires confirmation in independent patient cohorts.
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